My watch list
my.bionity.com  
Login  

Bimatoprost



Bimatoprost
Systematic (IUPAC) name
7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide
Identifiers
CAS number 155206-00-1
ATC code S01EE03
PubChem 5311027
DrugBank APRD00826
Chemical data
Formula C25H37NO4 
Mol. mass 415.566 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes Topical (eye drops)

Bimatoprost (sold in the U.S. and Canada by Allergan, under the trade name Lumigan) is a prostamide used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes.[1] It has also been used and prescribed off-label to lengthen eyelashes.[2]

Additional recommended knowledge

Contents

Cosmetic use

In patients using ophthalmic prostaglandins such as travoprost and latanoprost, as well as prostamides like bimatoprost, it has been anecdotally noted that they have grown long and lush eyelashes. Allergan has initiated clinical trials investigating the usage of Lumigan as a cosmetic drug.[3]

Several cosmetics companies have released products based on a prostaglandin analogs, as non-drug cosmetics.

  • Age Intervention Eyelash and Age Intervention Eyelash by Jan Marini Skin Research
  • RevitaLash by Athena Cosmetics Corp.
  • MD Lash Factor by PhotoMedex Inc.

These companies have been sued by Allergan for patent infringment.[3] The FDA has seized Age Intervention Eyelash as an "unapproved and misbranded drug" because Jan Marini Skin Research promoted it as something that increases eyelash growth[4] and because it is "adulterated" with bimatoprost.[5]

Formulations

Lumigan is a 0.03% solution of bimatoprost, and contains benzalkonium chloride as a preservative. Contact lenses should therefore be removed before use, and replaced no less than 15 minutes later;[1] other eye drops or ointments should be given no less than 5 minutes before or after bimatoprost.[1] It is administered once daily.

Side effects

Possible side effects of this medication are:

  • May cause optic nerve damage
  • May cause blurred vision;
  • May cause eyelid redness;
  • May permanently darken eyelashes;
  • May cause eye discomfort;
  • May eventually cause permanent darkening of the iris to brown (heterochromia).
  • May cause a temporary burning sensation during use.
  • May cause thickening of the eyelashes.

On November 19 2007 the FDA issued a warning that bimatoprost is associated with optic nerve damage. This warning was delivered by their spokesperson during the seizure of a bimatoprost-containing cosmetic.[6] Such warnings have not been issued for the prostaglandin analog derivatives, and may be specific to bimatoprost and the prostamide family.

References

  1. ^ a b c Bimatoprost Ophthalmic. MedlinePlus (January 1 2003). Retrieved on 2007-11-19.
  2. ^ "Drug That Lengthens Eyelashes Sets Off Flutter", The Wall Street Journal, 2007-11-19. Retrieved on 2007-11-19. 
  3. ^ a b Wall Street Journal: Drug That Lengthens Eyelashes Sets Off Flutter RHONDA L. RUNDLE November 19, 2007; Page B1
  4. ^ MSNBC: FDA Seizes $2 Million Of Potentially Harmful SJ Eye Product KNTV-TV 2:44 p.m. ET, Sat., Nov. 17, 2007
  5. ^ Reuters: U.S. seizes discontinued eyelash product Jim Wolf Fri Nov 16, 2007 11:48pm EST
  6. ^ U.S. Food and Drug Administration (November 19 2007). "Potentially Harmful "Cosmetic" Eye Product Seized". Press release. Retrieved on 2007-12-05.

Citations

  • Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188-93. PMID 16808680.
  • Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klin Monatsbl Augenheilkd 223 (6): 534-7. PMID 16804825.
  • Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177-9. PMID 16567279.


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bimatoprost". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE